Iterum Therapeutics Announces $20M Share Offering
Iterum Therapeutics (ITRM) announced a $20 million share offering under its at-the-market agreement on October 16, 2025. The company has previously raised $36.2 million through similar offerings. Despite launching ORLYNVAH™ in the U.S. in August 2025, the company faces financial challenges, including ongoing net losses. Analysts rate ITRM as a Buy with a $5.00 price target, but Spark's AI Analyst considers it an Underperform due to weak market momentum and strategic uncertainties. Iterum's current market cap is $32.94 million.
Iterum Therapeutics ( (ITRM) ) has issued an update.
On October 16, 2025, Iterum Therapeutics announced a prospectus supplement for the offer and sale of its ordinary shares, aiming to raise up to $20 million under its at-the-market offering agreement. The company has previously raised approximately $36.2 million through similar offerings. In August 2025, Iterum launched ORLYNVAH™ in the U.S. market, expecting modest sales in the early stages of its commercialization efforts.
The most recent analyst rating on (ITRM) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Iterum Therapeutics stock, see the ITRM Stock Forecast page.
Spark’s Take on ITRM Stock
According to Spark, TipRanks’ AI Analyst, ITRM is a Underperform.
Iterum Therapeutics faces significant financial challenges with ongoing net losses and cash flow issues, despite positive developments such as FDA approval of ORLYNVAH. The technical indicators suggest weak market momentum, and valuation metrics reflect poor investment attractiveness. The potential market for ORLYNVAH and improved financial performance are notable positives, but strategic uncertainties and financial obligations weigh heavily on the stock’s outlook.
To see Spark’s full report on ITRM stock, click here.
More about Iterum Therapeutics
Iterum Therapeutics is a pharmaceutical company involved in the development and commercialization of anti-infective treatments. The company focuses on the U.S. market, having recently launched its product ORLYNVAH™ into the community market.
Average Trading Volume: 873,361
Technical Sentiment Signal: Sell
Current Market Cap: $32.94M
